• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    18 Stocks Moving in Thursday's Pre-Market Session

    12/16/21 7:15:50 AM ET
    $ASRT
    $AVCT
    $CALT
    $CODX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $ASRT alert in real time by email

    Gainers

    • Calliditas Therapeutics AB (NASDAQ:CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.
    • CooTek (Cayman) Inc. (NYSE:CTK) rose 15.6% to $0.5589 in pre-market trading after dropping more than 10% on Wednesday.
    • Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) rose 13.5% to $3.26 in pre-market trading after gaining over 4% on Wednesday.
    • American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) rose 13.5% to $1.74 in pre-market trading after the company’s Kandy Communications business unit said that full Public Switched Telephone Network (PSTN) replacement services are now available in Brazil and China.
    • Retail Value Inc. (NYSE:RVI) rose 12.2% to $6.80 in pre-market trading after the company reported the sale of Willowbrook Plaza. The company reported a special common share distribution and preferred stock repurchase.
    • Tyme Technologies, Inc. (NASDAQ:TYME) rose 10.3% to $0.8165 in pre-market trading. TYME Technologies recently said TYME-19 'demonstrated an antiviral effect against SARS CoV-2 in human lung epithelial cells.'
    • Assertio Holdings, Inc. (NASDAQ:ASRT) rose 9.6% to $1.48 in pre-market trading after the company reported the acquisition of Otrexup® (methotrexate) a drug device combination from Antares Pharma, Inc.
    • Enveric Biosciences, Inc. (NASDAQ:ENVB) rose 7.5% to $1.14 in pre-market trading after declining over 6% on Wednesday.
    • Co-Diagnostics, Inc. (NASDAQ:CODX) rose 7.2% to $8.92 in pre-market trading. Co-Diagnostics reported a partnership with TiiCKER to 'increase its connection to retail investors.'
    • Canoo Inc. (NASDAQ:GOEV) rose 6.9% to $9.24 in pre-market trading after the company boosted production guidance and targets for US facilities.
    • HUTCHMED (China) Limited (NASDAQ:HCM) rose 6.9% to $34.09 in pre-market trading.
    • Legend Biotech Corporation (NASDAQ:LEGN) rose 6.7% to $43.90 in pre-market trading. Legend Biotech recently reported an offering of $300 million in ADSs.
    • Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) rose 6% to $1.23 in pre-market trading. Navidea Biopharmaceuticals terminated purchase agreement of $25 million worth of stock. The company also completed full enrollment in Phase 2b normative database study to support its rheumatoid arthritis program.


    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Check out these big penny stock gainers and losers

    Losers

    • IronNet, Inc. (NYSE:IRNT) fell 19.3% to $5.49 in pre-market trading after the company reported Q3 sales results were lower year over year.
    • Zhangmen Education Inc. (NYSE:ZME) fell 8.2% to $1.12 in pre-market trading.
    • Lennar Corporation (NYSE:LEN) shares fell 7.2% to $105.00 in pre-market trading after the company reported downbeat earnings for its fourth quarter. The company said it sees Q1 new orders of 14,800 to 15,100.
    • Danimer Scientific, Inc. (NYSE:DNMR) shares fell 6.5% to $9.90 in pre-market trading after the company reported a proposed convertible senior notes offering.
    • Inpixon (NASDAQ:INPX) fell 6.2% to $0.67 in pre-market trading after gaining around 7% on Wednesday.
    Get the next $ASRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASRT
    $AVCT
    $CALT
    $CODX

    CompanyDatePrice TargetRatingAnalyst
    Legend Biotech Corporation
    $LEGN
    1/22/2026$21.00Buy → Hold
    TD Cowen
    Lennar Corporation
    $LEN
    1/7/2026Mkt Outperform → Mkt Perform
    Citizens JMP
    Legend Biotech Corporation
    $LEGN
    1/7/2026$75.00Outperform
    Oppenheimer
    Lennar Corporation
    $LEN
    1/6/2026$122.00Buy → Neutral
    UBS
    Lennar Corporation
    $LEN
    12/18/2025$95.00Sector Perform → Underperform
    RBC Capital Mkts
    Lennar Corporation
    $LEN
    12/18/2025$92.00In-line → Underperform
    Evercore ISI
    Lennar Corporation
    $LEN
    12/18/2025$95.00Neutral → Underperform
    BofA Securities
    Lennar Corporation
    $LEN
    12/8/2025$98.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $ASRT
    $AVCT
    $CALT
    $CODX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/19/24 9:02:18 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/15/24 2:43:25 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/12/24 6:00:09 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $AVCT
    $CALT
    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Legend Biotech downgraded by TD Cowen with a new price target

    TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00

    1/22/26 8:26:15 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lennar downgraded by Citizens JMP

    Citizens JMP downgraded Lennar from Mkt Outperform to Mkt Perform

    1/7/26 8:57:14 AM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    Oppenheimer initiated coverage on Legend Biotech with a new price target

    Oppenheimer initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $75.00

    1/7/26 8:37:12 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $AVCT
    $CALT
    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai

    SALT LAKE CITY, Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in an exhibition at the upcoming World Health Expo Labs Dubai ("WHX Labs"), taking place February 10–13, 2026, at the Dubai World Trade Centre. World Health Expo Labs Dubai, formerly Medlab Middle East, is a multi-day international exhibition that convenes laboratory professionals, healthcare leaders, diagnostics develo

    2/9/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    HUTCHMED to Announce 2025 Final Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 202

    2/6/26 3:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument

    CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution SALT LAKE CITY, Feb. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has received a license from the Central Drugs Standard Control Organization ("CDSCO") to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument for sale or distribution.

    2/5/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $ASRT
    $AVCT
    $CALT
    $CODX
    SEC Filings

    View All

    SEC Form S-1 filed by Enveric Biosciences Inc.

    S-1 - Enveric Biosciences, Inc. (0000890821) (Filer)

    2/9/26 9:28:52 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

    2/6/26 4:45:30 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Enveric Biosciences Inc.

    424B5 - Enveric Biosciences, Inc. (0000890821) (Filer)

    2/6/26 4:30:15 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $AVCT
    $CALT
    $CODX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $AVCT
    $CALT
    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman & CEO Miller Stuart A was granted 230,118 shares and covered exercise/tax liability with 25,913 shares, increasing direct ownership by 21% to 1,168,244 units (SEC Form 4)

    4 - LENNAR CORP /NEW/ (0000920760) (Issuer)

    1/22/26 6:33:21 PM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    VP & Chief Financial Officer Bessette Diane J was granted 41,250 shares and covered exercise/tax liability with 6,871 shares, increasing direct ownership by 11% to 338,868 units (SEC Form 4)

    4 - LENNAR CORP /NEW/ (0000920760) (Issuer)

    1/22/26 6:20:52 PM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    VP & Controller Collins David M was granted 8,687 shares, increasing direct ownership by 20% to 52,630 units (SEC Form 4)

    4 - LENNAR CORP /NEW/ (0000920760) (Issuer)

    1/22/26 6:12:19 PM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    $ASRT
    $AVCT
    $CALT
    $CODX
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Lennar Announces the Retirement of Jonathan Jaffe, Co-CEO and President

    MIAMI, Nov. 14, 2025 /PRNewswire/ -- Lennar Corporation (NYSE:LEN), one of the nation's leading homebuilders, today announced that Lennar Co-Chief Executive Officer and President Jon Jaffe will retire effective December 31, 2025, following a distinguished 42-year career with the Company, and he will also step down from his role as a Director of the Board of the Company. After Mr. Jaffe's retirement, Stuart Miller will continue to serve as Executive Chairman and serve as Chief Executive Officer of Lennar, with no plans to replace Mr. Jaffe's role. Mr. Jaffe joined Lennar in 1983 as an assistant superintendent in Tampa, and through decades of hard work, unwavering commitment, and numerous val

    11/14/25 5:20:00 PM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $AVCT
    $CALT
    $CODX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $AVCT
    $CALT
    $CODX
    Financials

    Live finance-specific insights

    View All

    Lennar Corporation Declares Quarterly Dividends

    MIAMI, Jan. 21, 2026 /PRNewswire/ -- Lennar Corporation (NYSE:LEN), one of the nation's leading homebuilders, announced that its Board of Directors has declared a quarterly cash dividend of $0.50 per share for both Class A and Class B common stock payable on February 19, 2026 to holders of record at the close of business on February 4, 2026. About LennarLennar Corporation, founded in 1954, is one of the nation's leading builders of quality homes for all generations. Lennar builds affordable, move-up and active adult homes primarily under the Lennar brand name. Lennar's Financial Services segment provides mortgage financing, title and closing services primarily for buyers of Lennar's homes a

    1/21/26 4:30:00 PM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    Lennar Reports Fourth Quarter and Fiscal 2025 Results

    2025 Fourth Quarter Highlights Net earnings per diluted share of $1.93; $2.03 excluding adjustments of:$123 million mark-to-market gains on technology investments, and$156 million one-time loss on previously announced Millrose Properties, Inc. ("Millrose") exchange offerNet earnings of $490 millionNew orders increased 18% year over year to 20,018 homesBacklog of 13,936 homes with a dollar value of $5.2 billionDeliveries increased 4% year over year to 23,034 homesTotal revenues of $9.4 billionHomebuilding operating earnings of $718 millionGross margin on home sales of 17.0%; net margin of 9.1%Financial Services operating earnings of $134 millionMultifamily operating loss of $44 millionLennar

    12/16/25 4:30:00 PM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    Lennar Corporation to Broadcast Its Fourth Quarter Earnings Call on December 17, 2025

    MIAMI, Dec. 3, 2025 /PRNewswire/ -- Lennar Corporation (NYSE:LEN), one of the nation's largest homebuilders, announced today that the Company will release earnings for the fourth quarter ended November 30, 2025 after the market closes on December 16, 2025. Additionally, the Company will host a conference call on December 17, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast live and can be accessed through Lennar's website at investors.lennar.com. If you are unable to participate during the live webcast, the call will be archived at investors.lennar.com for 90 days.  Lennar Corporation, founded in 1954, is one of the nation's leading builders of quality homes for all generations.

    12/3/25 4:30:00 PM ET
    $LEN
    Homebuilding
    Consumer Discretionary

    $ASRT
    $AVCT
    $CALT
    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/14/24 3:52:50 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care